CANNABIS BIOSCI INTL HLDG - CBIH STOCK NEWS

Cannabis Bioscience International Holdings (CBIH) has engaged StoneBridge Advisory for a comprehensive company valuation. StoneBridge, a Colorado-based firm with over 30 years of experience, specializes in business valuations and mergers and acquisitions. This valuation aims to enhance strategic decision-making, attract investments, and facilitate negotiations, especially in light of potential U.S. federal reclassification of cannabis.

CBIH anticipates the valuation will help identify growth opportunities and navigate the evolving medical cannabis market. The company is preparing to capitalize on new business partnerships, funding, and banking services stemming from possible legal changes. The valuation is seen as essential for market comparison and long-term sustainability.

Cannabis Bioscience International Holdings (CBIH) has appointed Mr. John E. Jones as its new Treasurer and Director. Mr. Jones brings a wealth of experience from his successful career in the business sector, with a focus on strategic acquisitions, mergers, and capital projects. His expertise is expected to bolster CBIH's position in the cannabis industry, particularly in cannabinoid research and innovation.

Cannabis Bioscience International Holdings, Inc. (CBIH) initiates a clinical trial for Orthocann, a new intra-articular cannabinoid-based injection for knee osteoarthritis. The company aims to assess its efficacy in treating knee cartilage damage and providing relief without the adverse effects of corticosteroid injections.

Cannabis Bioscience International Holdings, Inc. (CBIH) announces the retirement of one billion shares by its CEO, Dante Picazo, contributing to a reduction in outstanding shares to approximately 9.4 billion. The market price of the shares is valued at $5 million, aiming to increase shareholder value. This move follows previous contributions by current management, totaling 5.5 billion shares since 2019, without a reverse stock split. The Company's commitment to innovation in medical formulations and biotechnology, supported by AI algorithms, reflects a focus on market integrity and scientific research.

Cannabis Bioscience International Holdings (CBIH) appoints Brian Cuban as Advisory Board Member, bringing legal, corporate leadership, and mental health expertise. Cuban, brother of Mark Cuban, is a lawyer, author, and advocate with a history of recovery. His addition aims to enhance CBIH's mission of advancing cannabinoid medicine and improving patient care.

Cannabis Bioscience International Holdings (CBIH) partners with Bull in Advantage for Investor Relations services.

Cannabis Bioscience International Holdings, Inc. (CBIH) CEO Dante Picazo sends a letter to shareholders, highlighting the company's progress in developing formulations for various medical conditions, including osteoarthritis and depressive disorders.

Cannabis Bioscience International Holdings (CBIH) achieved SEC effectiveness for its Form S-1 registration statement, aiming to start its own cannabis clinical trials using AI programs to optimize research processes and acquire clinical evidence for its intellectual property cannabinoid formulations. The company plans to treat cancer, PTSD, COVID-19, Herpes Zoster, chronic pain, and other conditions. CBIH is dedicated to representing Texas as a leader in the medicinal cannabis industry.

Cannabis Bioscience International Holdings, Inc. (CBIH) announces the declaration of its registration statement on Form S-1, filed under the Securities Act of 1933, as effective by the SEC. The company is offering 10,087,154,885 shares of its common stock at a price of $0.0008 per share, with 6,250,000,000 shares offered by the company and the remaining 3,837,154,885 shares by selling stockholders. The company has become a reporting company under Section 15(d) of the Securities Exchange Act of 1934, required to file annual, quarterly, and other reports with the SEC. The company offers services in clinical trials and cannabis-related education, intending to conduct clinical trials of its own cannabidiol products and sell them.